CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
The New England journal of medicine, 385(18): 1721-1722 PMID 34706179 DOI 10.1056/NEJMc2114592
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.